Results 141 to 150 of about 3,500 (185)

Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study. [PDF]

Inflamm Bowel Dis
Nakase H, Danese S, Reinisch W, Ritter T, Liang Y, Wendt E, Levesque BG, Yoon OK, Tian Y, Zhuo L, Karouzakis E, Bauer Y, Oortwijn A, Kaise T, Malkov VA, Hibi T.   +15 more
europepmc   +1 more source

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study. [PDF]

Aliment Pharmacol Ther
Osty M, Altwegg R, Serrero M, Benezech A, Lecomte A, Cadiot G, Vuitton L, Wampach A, Nancey S, Buisson A, le Berre C, Rouillon C, Gilletta C, Goutorbe F, Fumery M, Hammoudi N, Caillo L, Vidon M, Arab N, Sickersen G, Cavicchi M, Vieujean S, Charkaoui M, Richard N, Wils P, Caron B, Amiot A, Nuzzo A, Laharie D, Kirchgesner J, Uzzan M, GETAID‐J2J group.   +31 more
europepmc   +1 more source

Simultaneous Quantification of Filgotinib and Its Active Metabolite in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: Validation and Clinical Application. [PDF]

Biomed Chromatogr
Ito T, Suno M, Shintani M, Iwata A, Fujii T, Matsubara K.   +5 more
europepmc   +1 more source

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate. [PDF]

Rheumatology (Oxford)
Buch MH, Walker D, Edwards CJ, Barry J, Akroyd L, Ekoka Omoruyi EV, Taylor PC.   +6 more
europepmc   +1 more source

JAK-STAT inhibitors in noninfectious uveitis - A review. [PDF]

Indian J Ophthalmol
Pyare R, Shaikh N, Sen A, Kene R, Bagri N, Janarthanan M, Chawla R, Ramanan AV, Dutta Majumder P.   +8 more
europepmc   +1 more source

Dynamics of Serum Cytokines and Chemokines in Patients With Idiopathic Multicentric Castleman Disease: From a Phase Ib Investigator-Initiated Trial of Filgotinib. [PDF]

Cureus
Fukui S, Sumiyoshi R, Koga T, Hosogaya N, Narita S, Morimoto S, Yano H, Katsube A, Yano S, Masaki Y, Tsunoda S, Sato S, Migita K, Kawakami A.   +13 more
europepmc   +1 more source

In which patients with ulcerative colitis would filgotinib be effective? [PDF]

Intest Res
Park J.
europepmc   +1 more source

A Phase Ib Investigator-Initiated Trial of Filgotinib in Patients With Idiopathic Multicentric Castleman Disease. [PDF]

Cureus
Fukui S, Sumiyoshi R, Koga T, Hosogaya N, Narita S, Morimoto S, Yano H, Katsube A, Yano S, Masaki Y, Tsunoda S, Sato S, Migita K, Matsuyama K, Kato N, Kawamoto A, Kawakami A.   +16 more
europepmc   +1 more source

Efficacy of Filgotinib in Moderate to Severe Ulcerative Colitis: A Prospective Study Using Partial Mayo Score, Ulcerative Colitis Endoscopic Index of Severity, and Geboes Histopathology Score. [PDF]

Crohns Colitis 360
Shirouzu Y, Ishibashi H, Kage M, Mihara Y, Sakakibara Y, Nagata K, Suzuki A, Ohmiya T, Irie T, Araki Y, Mitsuyama K, Takedatsu H, Noake T.   +12 more
europepmc   +1 more source

JAK Inhibitors and B Cell Function: A Comparative Study of Their Impact on Plasma Cell Differentiation, Cytokine Production, and Naïve B Cell Activation. [PDF]

Eur J Immunol
Huang W, de Vries C, Sharma RK, Wangriatisak K, Chatzidionysiou K, Malmström V, Grönwall C.   +6 more
europepmc   +1 more source